Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiviUp is a nutraceutical supplement developed by the Australian company Entity Health, designed to mitigate hangover symptoms and support liver detoxification. Its primary active ingredient is dihydromyricetin (DHM), a flavonoid extracted from *Hovenia dulcis* (Japanese Raisin Tree). LiviUp functions by modulating GABA (gamma-aminobutyric acid) neurotransmitter activity in the brain and enhancing the activity of key liver enzymes, specifically alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), which accelerate the metabolism of alcohol and its toxic byproduct, acetaldehyde. It is marketed for the reduction of alcohol-related symptoms such as nausea, headache, and facial flushing. The product is manufactured in TGA and cGMP-compliant facilities in Victoria, Australia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LiviUp.